Corvus Pharmaceuticals Starts Enrollment In Its Phase 1b Clinical Study Of Soquelitinib To Treat Hidradenitis Suppurativa
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that enrollment has begun in its Phase 1b clinical trial of soquelitinib for the treatment of patients with
Corvus started testing a new medicine for a skin disease. When companies move forward with medicine trials, it shows progress, but results are still uncertain.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.